Sylvie Vincent

机构：Takeda (United States), Takeda (Japan) · ORCID：0000-0002-7247-2467

发表论文 140 篇 · 总被引 3286 次 · h-index 26

代表论文

• Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial (2023 · Journal of Thoracic Oncology · 被引 51)
• Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database (2024 · Journal of Thoracic Oncology · 被引 36)
• A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer (2023 · Gynecologic Oncology · 被引 12)
• Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity (2025 · Nature Communications · 被引 9)
• Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC. (2023 · Journal of Clinical Oncology · 被引 4)
• Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non–Small-Cell Lung Cancer According to ALK Fusion and Mutation Status (2025 · Clinical Lung Cancer · 被引 2)